A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod
ObjectiveTo characterize the post-marketing safety profile of etrasimod using the latest data from the FDA Adverse Event Reporting System (FAERS), and to provide a comparative analysis versus other sphingosine-1-phosphate (S1P) receptor modulators.MethodsAE reports associated with etrasimod were ret...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2025-11-01
|
| シリーズ: | Frontiers in Pharmacology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1693090/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|